Asenapine vs Olanzapine (Zyprexa)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Schizophrenia
Shared mechanism: Dopamine D2 and serotonin 5-HT2A receptors (antagonist) · full Schizophrenia pipeline
Asenapine
Marketed by AbbVie and partners
NCT00212784 · Phase 3 · completed
This 52-week trial randomly assigned 1,225 people with schizophrenia to asenapine or to olanzapine, with participants, carers, investigators and outcome assessors all unaware of assignment. The primary measure was change in total PANSS symptom score. Asenapine improved symptoms by 21.0 points against 27.5 points for olanzapine, a difference favouring olanzapine at p<0.0001, so asenapine was less effective than its active comparator on this measure.
Reported efficacy
Change in total PANSS score at endpoint (Screening, Week 76, 100, and once every 24 weeks thereafter until endpoint): Mean PANSS total score changes during first year of treatment were - 37.0 asenapine and - 35.3 olanzapine, with further changes of 1.6 asenapine and - 0.8 olanzapine at the extension study endpoint (unclear)
Result source: NCT00212771
Olanzapine (Zyprexa)
Marketed by Cheplapharm Arzneimittel GmbH and partners
NCT03510325 · Phase 3 · completed
This trial randomly assigned 762 people with schizophrenia to active antipsychotic treatments, with outcomes rated by masked assessors but treatment assignment itself not blinded. Among 111 participants who had not responded to first-line treatment and were reassigned to a second drug, 31.7% responded on olanzapine against 44.7% on amisulpride and 62.5% on clozapine, a significant difference across the three (p=0.03). Olanzapine was the least effective of the second-line options tested.
Next expected readout: February 2027 · NCT03781115 (registry estimate)
Reported efficacy
Treatment efficacy rate (baseline,0.5 months,1 months, 2 months,4 months , 6 months , 8 months and 12 months); All-cause dropout rate (baseline,0.5 months,1 months, 2 months,4 months , 6 months , 8 months and 12 months): Phase 2 symptomatic response (≥40% PANSS reduction) among 111 first-episode-treatment nonresponders re-randomized to second-line therapy: olanzapine 31.7% (13/41) vs amisulpride 44.7% (17/38) vs clozapine 62.5% (20/32); chi-square=6.9, P=.03 (missed)
Result source: NCT03510325
Results for Schizophrenia
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Asenapine | Olanzapine (Zyprexa) |
|---|---|---|
| PANSS total, change | -21.7 vs -16.2−5.5 vs placeboNCT0161718718 other results
| -8.8 vs 4.5−13.3 vs placeboNCT00686998 |
| CGI-S, change | -1.3 vs -0.8−0.5 vs placeboNCT0119025417 other results
| —Not posted · NCT00083668 |
| PANSS response | 39.3% vs 20.7%+18.6 vs placeboNCT010981101 other result
| 31.7% vs 44.7%avs amisulprideNCT03510325 |
| PSP, change | —Not posted · NCT00212771 | —Not posted · NCT00083668 |
| Relapse (% of patients) | —Not posted · NCT00212771 | —Not posted · NCT00083668 |
PANSS total, change
- Asenapine
- -21.7 vs -16.2−5.5 vs placeboNCT01617187
18 other results
- -12.2 vs -0.9 NCT01098110
- -25.5 vs -17.8 NCT01190254
- -14.2 vs -0.9 NCT01098110
- -17.4 vs -16.2 NCT01617187
- -23.7 vs -17.8 NCT01190254
- -17.1 vs -15.5 NCT01617187
- -14.8 vs -13.2 NCT01617187
- -19 vs -15.4 NCT01617187
- -12.5 vs -10.7 NCT01617187
- -9.1 vs -7.1 NCT01617187
- -4.9 vs -4.8 NCT01617187
- -12.3 vs -15.5 NCT01617187
- -12 vs -13.2 NCT01617187
- -17 vs -15.4 NCT01617187
- -9.9 vs -10.7 NCT01617187
- -7.2 vs -7.1 NCT01617187
- -4 vs -4.8 NCT01617187
- -21 vs -27.5 NCT00212784
- Olanzapine (Zyprexa)
- -8.8 vs 4.5−13.3 vs placeboNCT00686998
CGI-S, change
- Asenapine
- -1.3 vs -0.8−0.5 vs placeboNCT01190254
17 other results
- -1.2 vs -1 NCT01617187
- -0.7 vs -0.2 NCT01098110
- -1.1 vs -0.8 NCT01617187
- -0.9 vs -0.8 NCT01617187
- -0.8 vs -0.7 NCT01617187
- -0.6 vs -0.5 NCT01617187
- -0.3 vs -0.3 NCT01617187
- -0.2 vs -0.2 NCT01617187
- -0.8 vs -0.2 NCT01098110
- -1.1 vs -0.8 NCT01190254
- -0.9 vs -1 NCT01617187
- -0.9 vs -0.8 NCT01617187
- -0.7 vs -0.8 NCT01617187
- -0.6 vs -0.7 NCT01617187
- -0.6 vs -0.5 NCT01617187
- -0.3 vs -0.3 NCT01617187
- -0.1 vs -0.2 NCT01617187
- Olanzapine (Zyprexa)
- —Not posted · NCT00083668
PANSS response
- Asenapine
- 39.3% vs 20.7%+18.6 vs placeboNCT01098110
1 other result
- 43.8% vs 20.7% NCT01098110
- Olanzapine (Zyprexa)
- 31.7% vs 44.7%avs amisulprideNCT03510325
PSP, change
- Asenapine
- —Not posted · NCT00212771
- Olanzapine (Zyprexa)
- —Not posted · NCT00083668
Relapse (% of patients)
- Asenapine
- —Not posted · NCT00212771
- Olanzapine (Zyprexa)
- —Not posted · NCT00083668
- a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
3 other shared endpoints and safety
Coverage. Asenapine: 7 of 7 rows · Olanzapine (Zyprexa): 7 of 7 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Asenapine Rows use multiple source trials | Olanzapine (Zyprexa) Rows use multiple source trials |
|---|---|---|
| BMI absolute change · kg No placebo or comparator arm | 0.07 kg @ 52wka,b,c NCT01244828 · Phase 3 · registry result, not featured evidence | 2.83 kg @ 52wkd,a,b,c NCT00982020 · Phase 4 · registry result, not featured evidence · combination show 3 more doses2.99 kg @ 52wk NCT00982020 · Phase 4 · registry result, not featured evidence · combination 3.64 kg @ 52wk NCT00982020 · Phase 4 · registry result, not featured evidence · combination 3.36 kg @ 52wk NCT00982020 · Phase 4 · registry result, not featured evidence · combination |
| PANSS Total absolute change · score No placebo or comparator arm | -11.08 score @ 52wkd,e,c NCT01244828 · Phase 3 · registry result, not featured evidence show 1 more dose-5.48 score NCT01244828 · Phase 3 · registry result, not featured evidence | 0.3 score @ 330wke,c NCT00088465 · Phase 3 · registry result, not featured evidence |
| Weight absolute change · kg No placebo or comparator arm | 0.25 kg @ 52wke,f NCT01244828 · Phase 3 · registry result, not featured evidence | 2.76 kg @ 22wkd,e,f NCT00401973 · Phase 3 · registry result, not featured evidence show 2 more doses2.4 kg @ 22wk NCT00401973 · Phase 3 · registry result, not featured evidence · combination 0.65 kg @ 22wk NCT00401973 · Phase 3 · registry result, not featured evidence · combination |
| Dropout rate | 44.4%5 mg twice dailyg NCT01549041 · Phase 4 · registry result, not featured evidence show 23 more results16.7%10 mg daily in the evening NCT01549041 · Phase 4 · registry result, not featured evidence 54.8%5/10 mg BID NCT01142596 · Phase 3 · registry result, not featured evidence 0%5 mg BID NCT01617187 · Phase 3 · registry result, not featured evidence 1%2.5 mg BID NCT01617187 · Phase 3 · registry result, not featured evidence 49.7% NCT01244828 · Phase 3 · registry result, not featured evidence 35.2%5 mg BID NCT01098110 · Phase 3 · registry result, not featured evidence 40.1%10 mg BID NCT01098110 · Phase 3 · registry result, not featured evidence 50%Asenapine - Participants Who Were NCT01190267 · Phase 3 · registry result, not featured evidence 20.9%Asenapine - Participants Who Were NCT01190267 · Phase 3 · registry result, not featured evidence 20.8%5.0 mg BID NCT01190254 · Phase 3 · registry result, not featured evidence 17.3%2.5 mg BID NCT01190254 · Phase 3 · registry result, not featured evidence 33.7% NCT00174265 · Phase 3 · registry result, not featured evidence 50.4% NCT00145496 · Phase 3 · registry result, not featured evidence 30.4% NCT00150176 · Phase 3 · registry result, not featured evidence 15.7% NCT00265343 · Phase 3 · registry result, not featured evidence 67.7% NCT00156065 · Phase 3 · registry result, not featured evidence 0%5 mg NCT01206517 · Phase 1 · registry result, not featured evidence 33.3%10 mg NCT01206517 · Phase 1 · registry result, not featured evidence —10 mg NCT01206517 · Phase 1 · registry result, not featured evidence 0%10 mg NCT01206517 · Phase 1 · registry result, not featured evidence 25%10 mg NCT01206517 · Phase 1 · registry result, not featured evidence 0%10 mg NCT01206517 · Phase 1 · registry result, not featured evidence 0%2.5 mg NCT01206517 · Phase 1 · registry result, not featured evidence | 63.4%Olanzapine/Intense Behavioral Weigg NCT00982020 · Phase 4 · registry result, not featured evidence · combination show 14 more results55.9%Olanzapine/Standard Behavioral Wei NCT00982020 · Phase 4 · registry result, not featured evidence · combination 38.2% NCT00190749 · Phase 4 · registry result, not featured evidence 60.3% NCT00088465 · Phase 3 · registry result, not featured evidence 0% NCT00797277 · Phase 3 · registry result, not featured evidence 22%Olanzapine NCT00401973 · Phase 3 · registry result, not featured evidence 34.2%Olanzapine + Amantadine NCT00401973 · Phase 3 · registry result, not featured evidence · combination 31.5%Olanzapine + Metformin NCT00401973 · Phase 3 · registry result, not featured evidence · combination 18.2% NCT00686998 · Phase 2 · registry result, not featured evidence —Cohort 1: Olanzapine (Fast-D) NCT06319170 · Phase 1 · registry result, not featured evidence —Cohort 2: Olanzapine (To-be-market NCT06319170 · Phase 1 · registry result, not featured evidence —Cohort 3: Olanzapine (Slow-C) NCT06319170 · Phase 1 · registry result, not featured evidence —3 mg NCT00512070 · Phase na · registry result, not featured evidence · combination —0.3 mg NCT00512070 · Phase na · registry result, not featured evidence · combination —Olanzapine Only NCT00512070 · Phase na · registry result, not featured evidence |
| Discontinued due to AEs | 22.2%5 mg twice dailyg NCT01549041 · Phase 4 · registry result, not featured evidence show 23 more results0%10 mg daily in the evening NCT01549041 · Phase 4 · registry result, not featured evidence 22.3%5/10 mg BID NCT01142596 · Phase 3 · registry result, not featured evidence 0%5 mg BID NCT01617187 · Phase 3 · registry result, not featured evidence 0%2.5 mg BID NCT01617187 · Phase 3 · registry result, not featured evidence 23.6% NCT01244828 · Phase 3 · registry result, not featured evidence 17%5 mg BID NCT01098110 · Phase 3 · registry result, not featured evidence 17.6%10 mg BID NCT01098110 · Phase 3 · registry result, not featured evidence 0%Asenapine - Participants Who Were NCT01190267 · Phase 3 · registry result, not featured evidence 5.1%Asenapine - Participants Who Were NCT01190267 · Phase 3 · registry result, not featured evidence 7.5%5.0 mg BID NCT01190254 · Phase 3 · registry result, not featured evidence 6.1%2.5 mg BID NCT01190254 · Phase 3 · registry result, not featured evidence 8.1% NCT00174265 · Phase 3 · registry result, not featured evidence 17.2% NCT00145496 · Phase 3 · registry result, not featured evidence 8.2% NCT00150176 · Phase 3 · registry result, not featured evidence 7.5% NCT00265343 · Phase 3 · registry result, not featured evidence 11.8% NCT00156065 · Phase 3 · registry result, not featured evidence —5 mg NCT01206517 · Phase 1 · registry result, not featured evidence —10 mg NCT01206517 · Phase 1 · registry result, not featured evidence —10 mg NCT01206517 · Phase 1 · registry result, not featured evidence —10 mg NCT01206517 · Phase 1 · registry result, not featured evidence —10 mg NCT01206517 · Phase 1 · registry result, not featured evidence —10 mg NCT01206517 · Phase 1 · registry result, not featured evidence —2.5 mg NCT01206517 · Phase 1 · registry result, not featured evidence | 14.9%Olanzapine/Intense Behavioral Weigg NCT00982020 · Phase 4 · registry result, not featured evidence · combination show 14 more results18.6%Olanzapine/Standard Behavioral Wei NCT00982020 · Phase 4 · registry result, not featured evidence · combination 0% NCT00190749 · Phase 4 · registry result, not featured evidence 8.3% NCT00088465 · Phase 3 · registry result, not featured evidence — NCT00797277 · Phase 3 · registry result, not featured evidence 4%Olanzapine NCT00401973 · Phase 3 · registry result, not featured evidence 10.5%Olanzapine + Amantadine NCT00401973 · Phase 3 · registry result, not featured evidence · combination 5.5%Olanzapine + Metformin NCT00401973 · Phase 3 · registry result, not featured evidence · combination 4.5% NCT00686998 · Phase 2 · registry result, not featured evidence —Cohort 1: Olanzapine (Fast-D) NCT06319170 · Phase 1 · registry result, not featured evidence —Cohort 2: Olanzapine (To-be-market NCT06319170 · Phase 1 · registry result, not featured evidence —Cohort 3: Olanzapine (Slow-C) NCT06319170 · Phase 1 · registry result, not featured evidence —3 mg NCT00512070 · Phase na · registry result, not featured evidence · combination —0.3 mg NCT00512070 · Phase na · registry result, not featured evidence · combination —Olanzapine Only NCT00512070 · Phase na · registry result, not featured evidence |
| Serious AEs | 0%5 mg twice dailyg NCT01549041 · Phase 4 · registry result, not featured evidence show 23 more results0%10 mg daily in the evening NCT01549041 · Phase 4 · registry result, not featured evidence 20.4%5/10 mg BID NCT01142596 · Phase 3 · registry result, not featured evidence 4.4%5 mg BID NCT01617187 · Phase 3 · registry result, not featured evidence 5.2%2.5 mg BID NCT01617187 · Phase 3 · registry result, not featured evidence 8.9% NCT01244828 · Phase 3 · registry result, not featured evidence 5.7%5 mg BID NCT01098110 · Phase 3 · registry result, not featured evidence 2.8%10 mg BID NCT01098110 · Phase 3 · registry result, not featured evidence 12.5%Asenapine - Participants Who Were NCT01190267 · Phase 3 · registry result, not featured evidence 3.6%Asenapine - Participants Who Were NCT01190267 · Phase 3 · registry result, not featured evidence 2.8%5.0 mg BID NCT01190254 · Phase 3 · registry result, not featured evidence 3.1%2.5 mg BID NCT01190254 · Phase 3 · registry result, not featured evidence 4.7% NCT00174265 · Phase 3 · registry result, not featured evidence 12.3% NCT00145496 · Phase 3 · registry result, not featured evidence 3.1% NCT00150176 · Phase 3 · registry result, not featured evidence 6.7% NCT00265343 · Phase 3 · registry result, not featured evidence 14.1% NCT00156065 · Phase 3 · registry result, not featured evidence 0%5 mg NCT01206517 · Phase 1 · registry result, not featured evidence —10 mg NCT01206517 · Phase 1 · registry result, not featured evidence 0%10 mg NCT01206517 · Phase 1 · registry result, not featured evidence —10 mg NCT01206517 · Phase 1 · registry result, not featured evidence —10 mg NCT01206517 · Phase 1 · registry result, not featured evidence —10 mg NCT01206517 · Phase 1 · registry result, not featured evidence 0%2.5 mg NCT01206517 · Phase 1 · registry result, not featured evidence | 19.8%Olanzapine/Intense Behavioral Weigg NCT00982020 · Phase 4 · registry result, not featured evidence · combination show 14 more results12.7%Olanzapine/Standard Behavioral Wei NCT00982020 · Phase 4 · registry result, not featured evidence · combination 2.9% NCT00190749 · Phase 4 · registry result, not featured evidence 18.3% NCT00088465 · Phase 3 · registry result, not featured evidence 0% NCT00797277 · Phase 3 · registry result, not featured evidence —Olanzapine NCT00401973 · Phase 3 · registry result, not featured evidence —Olanzapine + Amantadine NCT00401973 · Phase 3 · registry result, not featured evidence · combination —Olanzapine + Metformin NCT00401973 · Phase 3 · registry result, not featured evidence · combination 0% NCT00686998 · Phase 2 · registry result, not featured evidence 0%Cohort 1: Olanzapine (Fast-D) NCT06319170 · Phase 1 · registry result, not featured evidence 3.2%Cohort 2: Olanzapine (To-be-market NCT06319170 · Phase 1 · registry result, not featured evidence 0%Cohort 3: Olanzapine (Slow-C) NCT06319170 · Phase 1 · registry result, not featured evidence 0%3 mg NCT00512070 · Phase na · registry result, not featured evidence · combination 25%0.3 mg NCT00512070 · Phase na · registry result, not featured evidence · combination 5.9%Olanzapine Only NCT00512070 · Phase na · registry result, not featured evidence |
| Most frequent reported AEs | 5 mg twice dailyg daytime drowsiness 22.2% NCT01549041 · Phase 4 · registry result, not featured evidence show 19 more results10 mg daily in the evening daytime drowsiness 0% NCT01549041 · Phase 4 · registry result, not featured evidence 5/10 mg BID nasopharyngitis 21.7% schizophrenia 10.8% somnolence 10.8% NCT01142596 · Phase 3 · registry result, not featured evidence 5 mg BID insomnia 15% (placebo 13.9%) headache 8.8% (placebo 2%) anxiety 7.1% (placebo 11.9%) NCT01617187 · Phase 3 · registry result, not featured evidence 2.5 mg BID headache 10.3% (placebo 2%) insomnia 9.3% (placebo 13.9%) anxiety 7.2% (placebo 11.9%) NCT01617187 · Phase 3 · registry result, not featured evidence nasopharyngitis 21% somnolence 12.7% weight increased 12.7% NCT01244828 · Phase 3 · registry result, not featured evidence 5 mg BID akathisia 11.4% (placebo 5.2%) hypoaesthesia oral 10.9% (placebo 3.4%) insomnia 9.7% (placebo 12.1%) NCT01098110 · Phase 3 · registry result, not featured evidence 10 mg BID schizophrenia 13.8% (placebo 24.1%) somnolence 12.2% (placebo 1.7%) akathisia 10.5% (placebo 5.2%) NCT01098110 · Phase 3 · registry result, not featured evidence accidental overdose 12.5% acne 12.5% akathisia 12.5% NCT01190267 · Phase 3 · registry result, not featured evidence somnolence 14.8% headache 6.6% sedation 5.1% NCT01190267 · Phase 3 · registry result, not featured evidence 5.0 mg BID somnolence 17% (placebo 6.9%) sedation 11.3% (placebo 2%) insomnia 9.4% (placebo 5.9%) NCT01190254 · Phase 3 · registry result, not featured evidence 2.5 mg BID somnolence 20.4% (placebo 6.9%) dizziness 7.1% (placebo 1%) headache 7.1% (placebo 5.9%) NCT01190254 · Phase 3 · registry result, not featured evidence insomnia 10.6% weight increased 5.9% headache 2.4% NCT00174265 · Phase 3 · registry result, not featured evidence insomnia 17.6% somnolence 14.8% headache 13.5% NCT00145496 · Phase 3 · registry result, not featured evidence insomnia 20.1% (placebo 24.5%) somnolence 16% (placebo 17.2%) weight increased 14.4% (placebo 10.9%) NCT00150176 · Phase 3 · registry result, not featured evidence headache 5.2% influenza 5.2% schizophrenia 5.2% NCT00265343 · Phase 3 · registry result, not featured evidence insomnia 18.5% headache 10.9% parkinsonism 10.9% NCT00156065 · Phase 3 · registry result, not featured evidence 5 mg dystonia 66.7% dizziness 33.3% nausea 33.3% NCT01206517 · Phase 1 · registry result, not featured evidence 10 mg hypoaesthesia oral 50% dizziness 38.9% dysgeusia 38.9% NCT01206517 · Phase 1 · registry result, not featured evidence 2.5 mg sedation 33.3% dysgeusia 16.7% hypoaesthesia oral 16.7% NCT01206517 · Phase 1 · registry result, not featured evidence | g somnolence 23.8% weight increased 20.8% headache 19.8% NCT00982020 · Phase 4 · registry result, not featured evidence · combination show 14 more resultsweight increased 30.4% headache 18.6% somnolence 18.6% NCT00982020 · Phase 4 · registry result, not featured evidence · combination weight increased 16.2% headache 10.3% sedation 10.3% NCT00190749 · Phase 4 · registry result, not featured evidence weight increased 14.4% anxiety 9.7% insomnia 9.7% NCT00088465 · Phase 3 · registry result, not featured evidence insomnia 10% somnolence 8% increased appetite 6% NCT00401973 · Phase 3 · registry result, not featured evidence somnolence 6.6% dry mouth 5.3% insomnia 5.3% NCT00401973 · Phase 3 · registry result, not featured evidence · combination diarrhoea 13.7% somnolence 11% nausea 6.8% NCT00401973 · Phase 3 · registry result, not featured evidence · combination weight increased 40.9% (placebo 0%) increased appetite 18.2% (placebo 2.4%) somnolence 18.2% (placebo 2.4%) NCT00686998 · Phase 2 · registry result, not featured evidence injection site irritation 6.9% injection site pain 6.9% psychotic disorder 6.9% NCT06319170 · Phase 1 · registry result, not featured evidence injection site pain 9.7% somnolence 9.7% blood creatine phosphokinase increased 6.5% NCT06319170 · Phase 1 · registry result, not featured evidence alanine aminotransferase increased 6.5% aspartate aminotransferase increased 6.5% somnolence 6.5% NCT06319170 · Phase 1 · registry result, not featured evidence 3 mg abnormal lab values 33.3% decreased appetite 16.7% depression 16.7% NCT00512070 · Phase na · registry result, not featured evidence · combination 0.3 mg abnormal lab values 50% depression 25% psychotic symptoms 25% NCT00512070 · Phase na · registry result, not featured evidence · combination abnormal lab values 29.4% insomnia/sleep disturbance 23.5% diarrhea 17.6% NCT00512070 · Phase na · registry result, not featured evidence |
Notes
- aTrial phases differ: Phase 4 versus Phase 3.
- bPopulation context differs: registered conditions differ.
- cTreatment context has not been resolved for both arms.
- dThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- ePopulation comparability has not been reviewed for both studies.
- fAssessment timepoints differ: 22 weeks versus 52 weeks.
- gPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Asenapine
show 1 more result
show 1 more result
show 17 more results
show 17 more results
show 2 more results
show 19 more results
show 15 more results
show 15 more results
show 17 more results
show 17 more results
show 17 more results
show 17 more results
+ 29 further endpoints in the CSV export.
Olanzapine (Zyprexa)
show 1 more result
show 1 more result
show 2 more results
show 1 more result
+ 11 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Asenapine's landscape · Olanzapine (Zyprexa)'s landscape